1. Rapid Intravenous Glyceryl Trinitrate in Ischemic Damage (RIGID): A potential neuroprotection strategy for acute ischemic stroke (AIS) patients
- Author
-
Lipeng Cai, Yuchuan Ding, Gary Rajah, Yanna Tong, Honglian Duan, Zhenzhen Han, Jie Gao, Zhe Cheng, Ruiqiang Xin, Shangqian Jiang, and Xiaokun Geng
- Subjects
Neuroprotection ,Nitric oxide ,Intravenous thrombolysis ,Randomized controlled trial ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Despite advances in intravenous thrombolysis and endovascular thrombectomy, numerous acute ischemic stroke survivors continue to experience various disability levels. The nitric oxide (NO) donor, Glyceryl Trinitrate (GTN), has been identified as a potential neuroprotective agent against ischemic damage. We evaluated the safety and feasibility of intravenous GTN in AIS patients. Subsequently, we conducted a secondary analysis to assess for possible efficacy of GTN as a neuroprotectant. We conducted a prospective, double-blind, randomized controlled trial in the Stroke Intervention & Translational Center (SITC) in Beijing Luhe Hospital, Capital Medical University (ChiCTR2100046271). AIS patients within 24 h of stroke onset were evenly divided into GTN or control groups (n = 20 each). The GTN group received intravenous GTN (5 mg in 50 ml saline at a rate of 0.4 mg/h for 12.5 h/day over 2 days), while controls were administered an equivalent volume of 0.9% saline. Both groups followed standard Stroke Guidelines for treatment. Safety measures focused on SBP
- Published
- 2024
- Full Text
- View/download PDF